A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)

NCT04994522 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

End Stage Renal Disease
Renal Impairment

Interventions

DRUG: Belzutifan

Sponsor

Merck Sharp & Dohme LLC